Corvus Pharmaceuticals Inc (CRVS)
1.92
+0.19
(+10.98%)
USD |
NASDAQ |
May 03, 16:00
2.05
+0.13
(+6.77%)
After-Hours: 20:00
Corvus Pharmaceuticals Research and Development Expense (Quarterly): 3.999M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.999M |
| September 30, 2023 | 3.965M |
| June 30, 2023 | 3.968M |
| March 31, 2023 | 4.594M |
| December 31, 2022 | 4.08M |
| September 30, 2022 | 10.36M |
| June 30, 2022 | 4.923M |
| March 31, 2022 | 5.10M |
| December 31, 2021 | 4.788M |
| September 30, 2021 | 6.991M |
| June 30, 2021 | 9.106M |
| March 31, 2021 | 8.23M |
| December 31, 2020 | 7.191M |
| September 30, 2020 | 6.619M |
| June 30, 2020 | 7.857M |
| March 31, 2020 | 10.16M |
| December 31, 2019 | 8.92M |
| September 30, 2019 | 8.996M |
| Date | Value |
|---|---|
| June 30, 2019 | 10.64M |
| March 31, 2019 | 9.419M |
| December 31, 2018 | 8.394M |
| September 30, 2018 | 8.374M |
| June 30, 2018 | 9.715M |
| March 31, 2018 | 12.10M |
| December 31, 2017 | 9.688M |
| September 30, 2017 | 10.73M |
| June 30, 2017 | 12.39M |
| March 31, 2017 | 13.50M |
| December 31, 2016 | 9.132M |
| September 30, 2016 | 7.707M |
| June 30, 2016 | 7.119M |
| March 31, 2016 | 5.397M |
| December 31, 2015 | 4.909M |
| September 30, 2015 | 2.514M |
| June 30, 2015 | 2.005M |
| March 31, 2015 | 1.924M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.965M
Minimum
Sep 2023
10.64M
Maximum
Jun 2019
6.868M
Average
6.991M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | 3.518M |
| Arbutus Biopharma Corp | 17.56M |
| Oragenics Inc | 11.04M |
| Relmada Therapeutics Inc | 14.75M |
| MAIA Biotechnology Inc | 3.717M |